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ARTICLE OPEN
Cost-effectiveness of initiating extraﬁne- or standard
size-particle inhaled corticosteroid for asthma in two
health-care systems: a retrospective matched cohort study
Richard J Martin1, David Price2,3, Nicolas Roche4, Elliot Israel5, Willem MC van Aalderen6, Jonathan Grigg7, Dirkje S Postma8,
Theresa W Guilbert9, Elizabeth V Hillyer3, Anne Burden3, Julie von Ziegenweidt3 and Gene Colice10
BACKGROUND: Real-life studies are needed to determine the cost-effectiveness of asthma therapies in clinical practice.
AIM: To compare the cost-effectiveness of extraﬁne-particle inhaled corticosteroid (ICS) with standard size-particle ICS in the United
Kingdom (UK) and United States (US).
METHODS: These retrospective matched cohort analyses used large electronic databases to study asthma-related outcomes for
patients in the UK (12–60 years old; n= 1730) and US (12–80 years; n= 10,312) prescribed extraﬁne beclomethasone or ﬂuticasone
as their ﬁrst ICS therapy for asthma. Patients were matched on demographic characteristics and asthma severity during 1 baseline
year, and asthma control and asthma-related costs were compared during 1 outcome year.
RESULTS: In both the UK and US, adjusted odds of risk-domain asthma control were similar, whereas the odds of overall control
(no hospitalisation or oral steroids for asthma, no antibiotics for lower respiratory infection, limited reliever use) were greater for
extraﬁne ICS in both countries (UK odds ratio, 1.23; 95% conﬁdence interval (CI), 1.01–1.50). Asthma-related annual costs, adjusted
for baseline, were signiﬁcantly lower for extraﬁne-particle ICS cohorts in both countries (UK difference, − £66 (95% CI,− 93 to − 37)).
Cost-effectiveness analyses using the two measures of asthma control found 92 and 98% probabilities of extraﬁne-particle ICS
being the preferred treatment strategy (less costly and more effective than standard size-particle ICS) in the UK, and 84 and 100%
probabilities in the US.
CONCLUSIONS: Initiating ICS therapy for asthma as extraﬁne-particle ICS seems the dominant treatment option (less costly and
more effective) compared with standard size-particle ICS in both the UK and the US.
npj Primary Care Respiratory Medicine (2014) 24, 14081; doi:10.1038/npjpcrm.2014.81; published online 9 October 2014
INTRODUCTION
Asthma is common and expensive, affecting ~ 1 in 12 adults in the
United Kingdom (UK) and 1 in 13 adults in the United States
(US).1–4 The annual economic burden of asthma was estimated
recently at 1 billion pounds (£) in costs for the UK National Health
Service (NHS) and 56 billion dollars ($) in direct costs and
productivity losses in the US.4,5 The costs of asthma are
disproportionately attributable to patients with poorly controlled
disease,6,7 highlighting the importance of maintaining asthma
control and minimising exacerbations, unscheduled consultations
and asthma-related hospitalisations.
Inhaled corticosteroids (ICSs) are ﬁrst-line therapy for the airway
inﬂammation present in persistent asthma.8,9 Although ICSs vary
in potency and formulation, little work has been done to compare
the cost-effectiveness of different ICSs used in real-life among the
varied patient populations seen in clinical practice. Real-life
studies are particularly pertinent for economic evaluations to
determine true comparative cost-effectiveness.10
In previous work,11,12 we analysed the real-life effectiveness of a
small-particle ICS, extraﬁne beclomethasone dipropionate, with
median mass aerodynamic diameter particle size of 1.1 μm,13,14
and a standard size-particle ICS, ﬂuticasone propionate (median
mass aerodynamic diameter, 2.4–3.2 μm, depending on
formulation15), for patients with asthma prescribed their ﬁrst ICS
or stepping up their ICS therapy in the UK and US. Patients
prescribed extraﬁne beclomethasone as their ﬁrst ICS experienced
similar or better asthma-related outcomes at lower doses
compared with patients prescribed ﬂuticasone. We hypothesised
that these effects could result from characteristics of the extraﬁne-
particle beclomethasone formulation and inhaler that enable
improved total and peripheral lung distribution as compared with
a larger-sized particle ICS.13,14
Our objective in this retrospective matched cohort study was to
compare the cost-effectiveness of initiating an extraﬁne-particle
ICS as compared with a representative standard size-particle ICS
for patients ⩾ 12 years old with asthma in the UK and US, two
countries with very different health-care systems.
MATERIALS AND METHODS
Effectiveness results and costs for the US cohorts, reported previously,12
are included here in brief to support the cost-effectiveness analyses.
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Study design and patients
We used de-identiﬁed patient data contained in two large, well-established
databases for these matched cohort analyses. The UK study drew on data
(January 1997 to June 2007) from primary care practices subscribing to the
General Practice Research Database, now the Clinical Practice Research
Datalink.16 The US study drew on data (2003–2010) contained in the
Ingenix Normative Health Information Database, now the OptumInsight
Research Database, an administrative claims database for primary and
secondary (specialist and emergency) medical care.12,17
We included data for patients prescribed their ﬁrst ICS for asthma by
means of a pressurised metered-dose inhaler as extraﬁne beclomethasone
(Qvar, Teva Pharmaceuticals, Petach Tikva, Israel) or ﬂuticasone (hydro-
ﬂuoroalkane or chloroﬂuorocarbon formulation; Flixotide, GlaxoSmithKline,
Brentford, UK). Patients in the UK prescribed extraﬁne beclomethasone by
breath-actuated inhaler were excluded from the analyses; extraﬁne
beclomethasone breath-actuated inhalers were not available in the US.
Patients aged 12–60 years in the UK and 12–80 years in the US were
eligible for the analyses.12 Each patient had complete up-to-standard data
for 1 year before (baseline year) and 1 year after (outcome year) the index
ICS prescription (Figure 1). We excluded patients with a diagnosis of any
chronic respiratory disease other than asthma and, in the US study,
patients who had received maintenance oral corticosteroid therapy during
baseline and smokers ⩾ 60 years to minimise inclusion of patients with
chronic obstructive pulmonary disease misdiagnosed as asthma.
Effectiveness measures
The two composite measures used to evaluate treatment effectiveness
were designed to capture both risk and current control aspects of asthma
control from the data sets (details in Supplementary Appendix), as per
consensus recommendations.18–20 We deﬁned risk-domain asthma control
as the absence of all of the following during the outcome year: (1) hospital
attendance for asthma, including inpatient, unscheduled outpatient, or
emergency department; (2) general practice consultation for lower
respiratory tract infection requiring antibiotics; and (3) an acute course
of oral corticosteroids. (Hospital attendance for asthma included all events
with a lower respiratory code—i.e., including all asthma codes and lower
respiratory tract infection codes.) Overall control (impairment and risk
domains of asthma control) was deﬁned as risk-domain asthma control plus
the fourth criterion of average daily use of ⩽ 2 puffs of salbutamol
(⩽200 μg in the UK and ⩽ 180 μg in the US study; Supplementary Table S1).
Resource use and costs
Information on asthma-related health-care resource use during baseline
and outcome years was extracted from the data sets and used to calculate
annual direct costs, including costs for all asthma- and lower respiratory-
related drugs, lower respiratory primary care consultations and respiratory-
related hospital attendance. Drug costs included those for ICSs, short-
acting β2-agonists (SABAs), long-acting β2-agonists (LABAs), combination
ICS-LABA inhalers, leukotriene receptor antagonists, theophylline, oral
corticosteroids and antibiotics.
The designated price year for the UK was 2007. Prices were derived from
national sources of cost data: namely, unit costs for general practice
resource use published by the Personal Social Services Research Unit;
British National Formulary for prescription use; and NHS Reference Costs
for hospital attendance.21–23
The designated price year for the US was 2010. Actual claimed costs
from the database, including both health plan and patient costs, were
adjusted to 2010 US$ using the Consumer Price Index for medical care.24
To account for the switch to more expensive hydroﬂuoroalkane inhalers in
2008, we used a standard 2010 price for SABA inhalers.
Cost-effectiveness analysis
The composite outcome measures and cost-effectiveness analyses were
prespeciﬁed according to the standard operating procedures of the
research group.25 The analyses were carried out using IBM SPSS
Statistics versions 19 and 20 (SPSS Statistics, IBM, Somers, NY, USA), SAS
versions 9.2 and 9.3 (SAS Institute, Marlow, UK) and Microsoft Excel 2007
(Microsoft, Bellevue, WA, USA). Statistically signiﬁcant results were deﬁned
as P⩽ 0.05.
We matched patients sequentially on the following criteria: sex, age and
criteria indicative of asthma severity at baseline, including number of acute
oral corticosteroid prescriptions during the year; mean daily SABA dose;
and (for the US only) number of asthma consultations with no acute oral
corticosteroid prescription (details in Supplementary Appendix). Matching
ratios, chosen to maximise patient numbers and statistical power for
comparisons, were 1:1 for the UK and 1:3 for the US for extraﬁne-particle
versus standard size-particle ICS cohorts.12
Summary statistics for baseline and unadjusted effectiveness
variables were tabulated by matched treatment cohort and compared
using conditional logistic regression. Total asthma-related and lower
respiratory-related health-care costs (hereafter called asthma-related costs)
were adjusted to 2007 (UK) or 2010 (US) prices, summed for baseline and
outcome years and compared between cohorts using conditional logistic
regression. Although the distributions were skewed, we report the
arithmetic mean costs, as recommended by Thompson et al.,26 because
means can be multiplied by a target population to estimate total costs, the
main outcome of interest for policy-makers and providers. The adjusted
odds of achieving risk-domain asthma control and overall control were
compared between matched cohorts using conditional binary logistic
regression models, with standard size-particle ICS as the reference
treatment. Asthma control status was used as the dependent variable,
with treatment and potential confounding factors (Supplementary
Table S2) as explanatory variables.
Expected differences in adjusted mean costs were modelled using
generalised linear models with gamma distributions to best ﬁt the data;
expected differences in adjusted proportions of patients achieving asthma
control were modelled using binomial distributions.26 The 95% conﬁdence
intervals (CIs) were determined by bootstrapping methods, using 1,000
random samples taken, with replacement, from the data set27; differences
(relative to standard size-particle ICS) were displayed graphically on a cost-
effectiveness plane. Further information on the methods of analysis is
detailed in the Supplementary Appendix.
RESULTS
Patients
After matching, there were 865 patients in each UK treatment
cohort (ages 12–60 years). The two cohorts were well matched for
baseline demographic and asthma-related characteristics, with no
clinically important differences (Table 1, Supplementary Table S3).
Inclusion: diagnostic code for
asthma +/or ≥2 asthma
prescriptions. No ICS therapy.
Standard size-particle ICS
pMDI
Index date:
Date of
ICS initiation
Baseline: 1 year
• Matching cohorts
• Confounding factor definition
Outcome: 1 year
• Outcome and cost comparison
• Adjusted for baseline confounders
Extrafine-particle ICS pMDI
Figure 1. Study design. ICS, inhaled corticosteroid; pMDI, pressurised metered-dose inhaler.
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Baseline characteristics of the 2,578 and 7,734 patients in the US
extraﬁne- and standard size-particle ICS cohorts were also well
matched, as previously described (see Supplementary Table S4).12
The UK and US cohorts had similar sex and age distributions, with
an additional 7% of US patients who were non-smokers ⩾ 60–80
years old. During the baseline period, the US patients were more
likely to have received oral corticosteroids and were less likely to
have achieved either risk-domain or overall control than the UK
patients. In the UK similar proportions of patients in the two
cohorts were prescribed a spacer; in the US a larger proportion of
patients prescribed standard size-particle ICS, compared with
those prescribed extraﬁne beclomethasone, were prescribed
spacers during baseline and/or outcome year (7% vs. 9%;
P= 0.006; Supplementary Table S5); however, the difference
between cohorts was small and likely not clinically signiﬁcant.
Effectiveness
The percentage of patients achieving risk-domain asthma control
in the UK study increased from 70% at baseline in both cohorts to
84% and 82% in extraﬁne-particle ICS and standard size-particle
ICS cohorts, respectively, during the outcome year. There was no
signiﬁcant difference between cohorts in the odds of achieving
risk-domain asthma control, with an adjusted odds ratio (OR) of
1.20 (95% CI, 0.93–1.57) for extraﬁne-particle ICS relative to
standard size-particle ICS. The percentage of patients achieving
overall control decreased from 65% at baseline in both cohorts to
63% and 58% during the outcome year in extraﬁne- and standard
size-particle ICS cohorts, respectively. Patients in the extraﬁne-
particle ICS cohort had signiﬁcantly higher odds of achieving
overall control (adjusted OR, 1.23; 95% CI, 1.01–1.50).
Effectiveness results for the US cohorts have been described in
detail elsewhere.12 In brief, the adjusted odds of achieving risk-
domain asthma control were similar for the two cohorts (adjusted
OR, 1.05; 95% CI, 0.96–1.15), whereas the odds of overall control
during the outcome year signiﬁcantly favoured extraﬁne-particle
ICS (adjusted OR, 1.19; 95% CI, 1.08–1.31).12
Resource use and costs
In the UK as in the US,12 extraﬁne beclomethasone was prescribed
at signiﬁcantly lower doses than ﬂuticasone on the index date
(median (interquartile range), 200 (100–200) vs. 500 (200–500)
μg/day in the UK, Po0.001). During the outcome year, the
median (interquartile range) daily ICS dose exposure was also
lower in extraﬁne beclomethasone compared with ﬂuticasone
cohorts at 110 (55–181) vs. 115 (41–247) μg/day in the UK and
44 (22–98) vs. 72 (36–195) μg/day in the US, respectively
(Po0.001 for both), although the difference was likely not
clinically signiﬁcant in the UK.
In the UK, mean asthma-related costs during the baseline year
were comparable between cohorts (Supplementary Table S6).
Over the outcome year, the mean total adjusted asthma-related
costs were signiﬁcantly lower in the extraﬁne-particle ICS cohort
both with and without the inclusion of ICS costs (Table 2); the
unadjusted costs are depicted in Supplementary Table S7.
In the US, drug and consultation costs during the baseline year
were signiﬁcantly higher for patients in the extraﬁne-particle ICS
cohort, whereas total annual asthma-related costs were compar-
able because of lower hospitalisation costs (Supplementary
Table S6). During the outcome year, the unadjusted asthma-
related costs were similar for both cohorts, as previously described
(see Supplementary Table S8).12
Cost-effectiveness
In the UK as in the US,12 total asthma-related costs during the
outcome year, when adjusted for baseline confounders, were
signiﬁcantly lower for patients prescribed extraﬁne-particle ICS
compared with standard size-particle ICS (Table 2). In the UK, the
adjusted mean difference (95% CI) of £66 (£37–£93) was driven
mainly by signiﬁcantly lower ICS costs in the extraﬁne-particle ICS
cohort (Tables 2 and 3).
The cost-effectiveness planes show the spread of the estimated
differences in cost and effectiveness based on 1000 replicated
samples (Figures 2 and 3). With regard to risk-domain asthma
control, the primary effectiveness measure, there was a 92% (UK)
or 84% (US) probability that extraﬁne-particle ICS was the
preferred treatment strategy (less costly and more effective) and
an 8% (UK) or 16% (US) probability that extraﬁne-particle ICS was
less costly but less effective (a trade-off; Figures 2a and 3a). With
regard to the overall control measure, after adjusting for potential
confounders, in the UK there was a 98% probability that extraﬁne-
particle ICS was the preferred treatment strategy, and a 2%
probability that extraﬁne-particle ICS was less costly but less
Table 1. Baseline characteristics of patients in the extraﬁne-particle
ICS and standard size-particle ICS cohorts in the UK
Characteristic UK study population
Extraﬁne ICS
(n= 865)
SSP ICS (n= 865)
Matching criteria
Female sex 516 (60) 516 (60)
Age at index date, years,
mean (s.d.)
38 (13) 38 (14)
Age 12–60 years 865 (100) 865 (100)
Nonsmokers aged ⩾ 60–80
years
n/a n/a
Oral corticosteroid courses
0 721 (83) 721 (83)
1 118 (14) 118 (14)
2 22 (3) 22 (3)
3 3 (0) 3 (0)
⩾ 4 1 (0) 1 (0)
Mean daily SABA dose (μg/day)
0 410 (47) 410 (47)
1–100 266 (31) 266 (31)
101–200 125 (15) 125 (15)
201–300 32 (4) 32 (4)
301–400 10 (1) 10 (1)
4400 22 (3) 22 (3)
Asthma consultation/no oral corticosteroidsa
0 468 (54) 467 (54)
1 326 (38) 298 (35)
⩾ 2 71 (8) 100 (12)
Effectiveness measures
Risk-domain asthma control 607 (70) 610 (71)
1 severe exacerbationb 108 (13) 114 (13)
⩾ 2 severe exacerbations 20 (2) 16 (2)
⩾ 1 course of antibiotics for
LRTI
169 (20) 166 (19)
⩾ 1 hospital attendance for
asthma
7 (1) 9 (1)
Overall control (risk and
impairment)
560 (65) 560 (65)
Data are n (%) unless otherwise stated. Percentages may not add up to
100% because of rounding.
Abbreviations: LRTI, lower respiratory tract infection; n/a, not applicable;
OCS, oral corticosteroid course; SABA, short-acting β-agonist; s.d., standard
deviation; SSP ICS, standard size-particle inhaled corticosteroid.
aMatching criterion for US study only.
bA severe exacerbation was deﬁned as an acute course of oral
corticosteroids or unscheduled hospital admission or emergency depart-
ment attendance for asthma.
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effective (Figure 2b). In the US, extraﬁne-particle ICS was less
costly (100%) and more effective (100%) and thus the dominant
treatment (Figure 3b).
DISCUSSION
Main ﬁndings
The results of these cost-effectiveness analyses indicate that
extraﬁne-particle ICS is likely to be the dominant treatment
strategy (less costly and more effective), as compared with
standard size-particle ICS, in both the UK and the US for patients
prescribed ICS for the ﬁrst time for asthma. In the UK, the
probabilities of extraﬁne-particle ICS being the preferred strategy
with regard to cost-effectiveness for risk-domain asthma control
and overall control were 92% and 98%, respectively; in the US, the
probabilities were 84% and 100%.
To our knowledge, this is the ﬁrst comparative cost-effectiveness
assessment of two ICSs in asthma performed using the same metrics
in two countries with very different health-care systems. The direct
asthma- and lower respiratory-related health-care costs, adjusted for
baseline costs, were signiﬁcantly lower for UK and US patients12
treated with extraﬁne-particle ICS with or without the inclusion of
ICS costs. The health-care systems in the UK and US, however, are
structured differently and, indeed, the absolute costs were very
different between the two countries, notably lower for the UK
primary care population than for US patients.
Interpretation of ﬁndings in relation to previously published work
For the UK, the mean unadjusted total asthma-related cost of
£155–218/year (depending on treatment cohort) was similar to
the annual cost to the NHS of £166/year (or £332 over 2 years)
reported for patients prescribed ICS in a recent UK pragmatic
Table 2. Outcome year asthma-related health-care costs after patients were initiated on ICS treatment (cost/patient per year) in the UK
Asthma-related resource UK study population (costs in 2007 UK£)
Extraﬁne ICS (n=865) SSP ICS (n=865) P valuea
Asthma-related medication 121 (311) 174 (421) 0.004
Asthma-related medication, excluding ICS 71 (301) 89 (384) 0.29
Asthma-related primary care consultation 25 (38) 30 (48) 0.008
Total asthma-related hospitalisations 9 (68) 14 (71) 0.17
Asthma-related inpatient 5 (63) 4 (58) 0.76
Asthma-related outpatient 4 (26) 9 (39) 0.001
Asthma-related emergency department 0 0 n/a
Asthma-related—other medical 0 0 n/a
Total unadjusted asthma-related costs, including ICS 155 (329) 218 (440) 0.001
Total unadjusted asthma-related costs, excluding ICS 104 (315) 132 (398) 0.12
Total adjusted costs per patientb (95% CI) 145 (131–160) 211 (190–232) o0.001
Total adjusted costs per patient, excluding ICS costsb (95% CI) 100 (89–112) 134 (116–154) 0.006
Asthma-related costs included all costs for lower respiratory-related health-care resource use. Values are mean (s.d.) unless otherwise noted. Mean values are
reported, despite substantially skewed distributions, because mean values can be multiplied by a target population to estimate total costs and thus are of
most interest for policy makers and providers. US costs are in Supplementary Table S8.
Abbreviations: CI, conﬁdence interval; n/a, not applicable; s.d., standard deviation; SSP ICS, standard size-particle inhaled corticosteroid.
aConditional logistic regression.
bAdjusted for baseline asthma-related health-care costs.
Table 3. Incremental cost-effectiveness analysis: effectiveness determined by risk-domain asthma control and overall control (risk and impairment)
UK study population US study population
Extraﬁne ICS (n= 865) SSP ICS (n= 865) Extraﬁne ICS (n=2578) SSP ICS (n=7734)
Adjusted OR for risk-domain asthma control 1.20 (0.93–1.57)a 1.00 1.05 (0.96–1.15)b 1.00
Adjusted proportion controlled 0.68 (0.60–0.76)a 0.64 (0.56–0.72) 0.52 (0.50–0.55)b 0.51 (0.49–0.53)
Difference relative to SSP ICS 0.04 (− 0.02–0.10) — 0.01 (− 0.01–0.04) —
Adjusted OR for overall control 1.23 (1.01–1.50)c 1.00 1.19 (1.08–1.31)d 1.00
Adjusted proportion controlled 0.50 (0.49–0.56)c 0.45 (0.40–0.50) 0.32 (0.31–0.34)d 0.29 (0.27–0.30)
Difference relative to SSP ICS 0.05 (0.001–0.10) — 0.04 (0.02–0.06) —
Adjusted mean asthma-related costs per patient per yeare £145 (131–160) £211 (190–232) $1869 ($1727–2032) $2259 ($2111–2404)
Difference relative to SSP ICS − £66 (− 93–− 37) — − $390 (− $620–− $165)
95% conﬁdence intervals (ranges in parentheses), other than those for ORs, were found using bootstrapping methods with 1000 random samples.
Costs are in 2007 UK£ and 2010 US$.
Abbreviations: OR, odds ratio; SSP ICS, standard size-particle inhaled corticosteroid.
aAdjusted for gastro-oesophageal reﬂux (GERD) diagnosis, number of consultations for lower respiratory tract infection (LRTI) resulting in a prescription for
antibiotics and number of non-asthma-related consultations.
bAdjusted for GERD diagnosis and/or therapy and numbers of paracetamol prescriptions, non-asthma-related consultations in primary care and lower
respiratory-related hospitalisations and referrals.
cAdjusted for GERD diagnosis, socioeconomic status and number of prescriptions for short-acting β-agonist.
dAdjusted for GERD diagnosis and/or therapy, year of index date, and numbers of paracetamol prescriptions, prescriptions for asthma/allergies, and lower
respiratory-related hospitalisations and referrals.
eAdjusted for baseline asthma-related health-care costs (logged).
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trial.28 With regard to effectiveness ﬁndings, as compared with our
prior study that included children as young as 5 years,11 the
proportions of patients achieving asthma control were roughly
similar, whereas the adjusted odds of risk-domain asthma control
were not signiﬁcantly different between treatment cohorts in the
present study (as we had found in the prior study11).
For the US, this study’s categorised costs were generally in line
with those reported recently by Barnett and Nurmagambetov,5
with the exception of respiratory-related medication costs, which
were lower by about $850/year in each cohort. Possible
explanations for the lower medication costs in our analyses are
(1) the exclusion of in-hospital medications from the study
database and (2) the inclusion of patients ⩾ 65 years of age
(3% of all patients) who used health-care resources covered by
Medicare that were not captured by the database. Our study’s
total costs ($1952–2369, depending on cohort) are thus lower
than the previously reported total per-patient annual incremental
cost of $3259 for asthma in 2009 US$.5,12
There are few economic evaluations comparing ICSs of different
particle sizes as monotherapy for asthma.29–31 In a 1-year
pragmatic, open-label study of adults with asthma, extraﬁne
beclomethasone was a cost-effective alternative when administered
at half the dose of the larger-particle chloroﬂuorocarbon
beclomethasone in the US, UK, Belgium and the Netherlands.32
More recently, in a 1-year US database study, signiﬁcantly lower
drug and total medical costs and fewer emergency department
visits were reported with extraﬁne beclomethasone compared with
ﬂuticasone for adults and children (5–64 years old) with persistent
asthma.33 Prior studies comparing extraﬁne beclomethasone and
ﬂuticasone were short-term (3–12 weeks) randomised trials that did
not evaluate cost-effectiveness.34
Strengths and limitations of this study
Our study has several potential limitations. As for any observa-
tional study using a large database, the analyses relied on the
accuracy and completeness of data recording. Some data were
not available for all patients, including socioeconomic status and
body mass index, both factors linked to asthma control; thus, we
cannot rule out the possibility of unrecognised confounding
factors. However, our matching process paired patients in each
cohort using several criteria reﬂective of asthma severity and
control at baseline, with subsequent adjustments for minor
residual confounding.
We used composite measures of asthma control to capture all
key elements of control (impairment and risk) that were available
from the database. The risk-domain asthma control measure
included the absence of criteria deﬁning severe exacerbations,18
which are important drivers of asthma-related costs. However, a
study limitation is that the databases, and thus our outcome
measures, do not capture symptoms or lung function measure-
ments. We included SABA prescriptions as a proxy for symptoms
in the ‘overall control’ measure, because SABA use reﬂects
symptom control. The control cutoff point of a mean SABA use
of ⩽ 2 puffs/day corresponds to the level 2 category (2 of 4, with 1
being the best controlled) of the validated approach of
Schatz et al.20 for SABA canister dispensing to assess asthma
symptom control. The deﬁnitions of the outcome measures are
Figure 2. UK Study: Cost-effectiveness planes for extraﬁne-particle
ICS relative to standard size-particle ICS matched cohort (adjusted
results): effectiveness based on (a) risk-domain asthma control and
(b) overall control (risk and impairment). The horizontal axis divides
probable costs (more expensive above, less expensive below) and
the vertical axis divides the probable effectiveness (less on the left,
more on the right).
Figure 3. US Study: Cost-effectiveness planes for extraﬁne-particle
ICS relative to standard size-particle ICS matched cohort (adjusted
results): effectiveness based on (a) risk-domain asthma control and
(b) overall control (risk and impairment).
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inherently related to the use of health-care resources; therefore, it
is unsurprising that costs and outcome in these analyses work in
the same direction. For the US analyses, the later index dates of
patients in the extraﬁne-particle ICS cohort12 might have biased
comparative costs, increasing the cost of extraﬁne-particle ICS and
decreasing the cost–beneﬁt relative to standard size-particle ICS,
despite the fact that costs were adjusted to 2010 dollars, because
of the general increases in costs over time.
A strength of these analyses is the consistency of results across
effectiveness measures and between the two countries. Moreover,
the large sample sizes reassure us of the robustness of the
ﬁndings. We evaluated outcomes over 12 months to eliminate
seasonal variations and evaluate long-term effects, as recom-
mended by expert group consensus.18,19 An important strength is
the fact that cost and effectiveness data were drawn from large
numbers of patients in real-life clinical practice, as opposed to
economic modelling based on non-representative clinical trial
data, which is the most common approach. Studied patients thus
included smokers, patients with comorbidities and potentially
those with poor adherence or poor inhaler technique, enhancing
the applicability of the ﬁndings to real-life practice.
Implications for future research, policy and practice
Calculations of indirect costs would have been of interest, as
patients with asthma have signiﬁcantly higher work loss than
those without,35 and recent estimates put lost productivity
because of asthma at 8–12% of the total societal burden of
asthma in the US.5 Moreover, continuing research is needed to
better characterise the role of small airway disease in asthma and
the beneﬁts of extraﬁne-particle ICS for treating both large
and small airway inﬂammation.36 Comparisons of other extraﬁne-
and larger-particle ICS are needed, and our ﬁndings should not be
extended beyond this comparison of extraﬁne beclomethasone
and ﬂuticasone.
A direct comparison between clinical outcomes in the US and UK
would be inappropriate because of differences between the
databases and health-care systems. However, several observations
are intriguing. The percentage of patients meeting the asthma control
measures was much lower, for both control measures, in the US12
than in the UK during baseline as well as outcome. We do not have an
obvious explanation for this observation but have marked it as a topic
for further study. In the US there was a greater disparity than in the
UK between dose prescribed at the index date and dose exposure
during the outcome year, possibly indicating poor adherence to
therapy. A change in therapy in the form of an increase in ICS dose or
additional therapy was more frequent in the US than in the UK (see
Supplementary Appendix). The percentages of patients achieving risk-
domain asthma control increased from baseline during the outcome
year in both treatment cohorts in the UK and US, although the
increase was small (1%) in the US.12 However, the percentages
achieving overall control decreased, likely driven by increased SABA
prescriptions during the outcome year, as noted in our prior
studies,11,12 for patients newly diagnosed with persistent asthma
who were prescribed additional SABA together with ICS.
Conclusions
Real-life comparative effectiveness and cost-effectiveness analyses
are needed to guide practical decision making with regard to
asthma therapies. These analyses serve as preliminary evidence of
the relative cost-effectiveness of extraﬁne-particle ICS and suggest
that initiating ICS therapy for asthma as extraﬁne-particle ICS is the
dominant treatment option (less costly and more effective) as
compared with standard size-particle ICS for adults and children
⩾ 12 years old in both the UK and US. Further studies, including
prospective pragmatic trials, are warranted to investigate the
comparative effectiveness and cost-effectiveness of other
examples of extraﬁne- and larger-particle ICS.
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